Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 + Pembrolizumab in Liver Metastases from CRC/Gastric Cancer
NCT04508140Phase 2Terminated
- Sponsor
- Highlight Therapeutics
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of nanoplexed poly I:C in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Highlight Therapeutics. Started Jun 2020; status: terminated.
02
Drugs
nanoplexed poly I:C
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04508140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508140.